Incivek regulatory update

FDA updated the label of Incivek telaprevir from Vertex to include a boxed warning that patients experiencing a rash with systemic symptoms or a progressive severe rash should immediately stop treatment of the HCV drug and peginterferon alfa and ribavirin. FDA said it has received reports of serious skin reactions in patients taking Incivek, some of which were fatal after patients continued to receive Incivek combination treatment after developing a worsening or progressive rash and systemic symptoms. Incivek is a small molecule HCV NS3/4A protease inhibitor. ...